TORQUE BIO
About
Serious genetic kidney diseases represent a significant unmet need, with few treatment options that address the underlying cause of disease. Torque Bio was created to help change that.
Torque Bio is developing next-generation genetic medicines for serious kidney disease, beginning with autosomal dominant polycystic kidney disease, a leading genetic cause of kidney failure. Our platform brings together proprietary kidney-optimized AAV vectors, gene replacement and AAV:circular RNA technologies, and targeted local delivery to the kidney. This integrated approach is designed to address disease biology at its source and advance durable, precise therapies for patients with high unmet need.
Senior Leadership
Board Members
Investors
Featured Presentation
Autosomal dominant polycystic kidney disease is a leading genetic cause of kidney failure, yet there are still no curative treatment options that address the root cause of the disease. In this ASGCT presentation, Torque Bio shares how its kidney-targeted gene therapy platform is being developed to overcome long-standing barriers in renal gene therapy. The presentation highlights Torque’s proprietary kidney-optimized delivery technology, direct-to-kidney administration approach, and early preclinical data across two programs targeting the major genetic drivers of ADPKD.
Download
Foundational Publications
Evolving adeno-associated viruses for gene transfer to the kidney via cross-species cycling of capsid libraries
Nature Biomedical Engineering, 2025
Engineering highly efficient backsplicing and translation of synthetic circRNAs
Molecular Therapy: Nucleic Acids, 2021
Tissue-Dependent Expression and Translation of Circular RNAs with Recombinant AAV Vectors In Vivo
Molecular Therapy: Nucleic Acids, 2018
Contact Us
Interested in learning more about Torque Bio’s platform, pipeline, or investment opportunities? Connect with our team.
8 Davis Drive Durham, NC 27713
"*" indicates required fields